News
Me is proposing to reopen its bankruptcy auction to entertain a final offer from a nonprofit operated by its co-founder, ...
Me has a path to a higher purchase price than the $256 million offered by biotech giant Regeneron after the genetic-testing ...
Bankrupt genetic testing company 23andMe told a U.S. bankruptcy judge on Wednesday that it wants to re-open bidding on its ...
2hon MSN
Twenty-seven states and the District of Columbia have filed a lawsuit in bankruptcy court seeking to block the sale of ...
Regeneron Pharma stock has been in a persistent downtrend for over 280 days. Here's why you should avoid REGN.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) 46th Annual Goldman Sachs Global Healthcare Conference June 9, 2025 10:40 AM ETCompany ...
Atopic dermatitis manifests differently in patients with darker skin color, according to the companies, including subtler presentations and more severe and prolonged lesions compared to patients with ...
14h
Clinical Trials Arena on MSNRegeneron and Sanofi’s dupilumab shows promise in AD trialRegeneron Pharmaceuticals and Sanofi have announced promising outcomes from the open-label Phase IV DISCOVER trial of ...
6d
Pharmaceutical Technology on MSNRegeneron to acquire rights for Hansoh’s HS-20094 therapyRegeneron Pharmaceuticals is to enter an in-licensing agreement with Hansoh Pharmaceuticals to secure exclusive rights for HS ...
Me (OTC:MEHCQ) faces a second auction after a $305M bid challenges Regeneron's (REGN) initial bid for its assets. Read more ...
The benefits of 52-week biologic therapy on asthma control and lung function are observed in both never smokers and ...
Interim results from the Phase II COURAGE trial show that combining semaglutide with anti-GDF8 antibody trevogrumab preserves ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results